Dow Jones 11097.79 -17.53 7:12 am PST, February 21, 2006  NASDAQ 2269.57 -12.79 For info, visit access.smallcapnetwork.com S & P 500 1286.48 -0.76 Change your subscription status here Russell 2000 732.08 +1.14 VOLUME 06: ISSUE 15  Feature: The Key to Defeating Cancer; Increasing Survival Rates. The bottom line to successful cancer treatment is relatively straightforward: the longer this deadly scourge can be held at bay or put into remission, the better a patient's chance of survival. That's a concept Big Pharma, which tends to focus on toxic end-of-life or chronic treatment drugs--has yet to grasp.  That's not the case with a lot of smallcap biotechs including unique cancer drug/therapeutics company CEL-SCI (AMEX: CVM). As we stated in our recent Trading Alert shares of CEL-SCI should be accumulated at these levels and on any dips by risk-oriented investors for what will be, in our opinion, superior gains over the next 6-12 months. As we saw in our previous coverage of CEL-SCI in 2002-2004, the shares can move quickly (21 cents to almost $2 in a few months) and decisively as investors wake up to the potential. Using recent volumes as our guide, we believe that we are on the threshold of a similar type of trading activity. At current levels, CVM appears to want to retrace a 5/8 move of the January 2005 high to the October 2005 low. The shares could well see 83 cents as a result before running into some resistance. Should they hit that level, we'll reassess. Shares of CVM have increased nicely --up 35 percent to 70-plus cents, Monday, from our recent Alert price of 52-cents.  Volumes have been robust and a sustained break above 60-65 cents would do well to move the shares up into a new and higher trading range. Investors will note that the shares have been consolidating between 50-60 cents for a while now. Improving Cancer Survival Rates Currently, the median survival rates for advanced primary head and neck cancer patients following traditional treatments are about 50 percent after 3 years. Apparently that patient survival number could well be about to rise significantly. In today's release (below), biotech CEL-SCI states that results from a 3-year follow-up to its previous Phase 2 Multikine study indicated that:  "Multikine-treated patients had substantially increased survival rates and achieved a higher rate of 2-year local regional control as compared to the survival and the 2-year local regional control rates published in the scientific literature." The "failure of local regional control" in Head and Neck Cancer is when the tumor recurs above the clavicle following surgery/therapy.  If it recurs, patients will die.  If it does not, they have a longer time to live or may be cured, unless it recurs in the lung.  As stated in the release, the endpoint of CEL-SCI's planned Phase 3 Multikine trial is to show significantly improved survival rates as well as enhanced regional control of tumors. Precise results from CEL-SCI's long-term Phase 2 follow-up cannot be released just yet due to the data being prepared for publication. In our opinion, it is reasonable to assume that they will likely prove to be very good. Think of the Head and Neck Cancer results as a potential 'proof of concept' for Multikine. Efficacy with this aggressive form of the cancer, which has had little treatment improvement over the last two decades, will likely translate into treatments for other forms of cancer--which we have noted in the past-- as well. Canada has already approved a Phase 3 trial and hopefully the FDA will follow suit soon. We think both are extremely exciting developments for both CEL-SCI and its shareholders. When compared to other Phase2/3 companies, CVM's market cap of around $45 million is a mere shadow of its peers. The majority of these companies, like CVM, make no revenue to speak of yet, but have been bid up significantly by investors who see the potential. Investors have apparently ignored the potential of CVM, which we feel is both a mistake and, more importantly, an opportunity for those risk-oriented shareholders who decide to participate now.   PRESS RELEASE Multikine Treatment Increases Survival in Cancer Patients Feb 21, 2006 10:07:00 AM VIENNA, Va., Feb. 21 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announces positive results from a long-term follow-up study of head & neck cancer patients treated with its drug Multikine(R) in a Phase II clinical trial. The follow-up study indicated that Multikine treatment resulted in a substantial increase in the survival of patients. In addition, Multikine treatment also improved local regional control of the patients' tumors. Improved local regional control of the tumor is considered by many surgeons and oncologists to be an important measurement of the success of a head & neck cancer drug. Both survival and local regional control of the tumor are stated endpoints in CEL-SCI's planned Phase III clinical trial. The Phase II study, which used the same Multikine treatment protocol as proposed for the Phase III trial, included advanced primary head & neck cancer patients who were scheduled for their first cancer treatment. The Multikine treatment was administered for 3 weeks prior to the standard treatment for head & neck cancer, surgery or surgery plus radiation/chemotherapy. Results from this study were published in a leading cancer publication, the Journal of Clinical Oncology (Timar et al, JCO, 23(15): May 2005). The median follow-up period for the patients was 3.2 years. The results of the Phase II trial follow-up study showed that the Multikine-treated patients had substantially increased survival rates and achieved a higher rate of 2-year local regional control as compared to the survival and the 2-year local regional control rates published in the scientific literature (39 clinical trials between 1987 and 2004 in a similar population of head & neck cancer patients). At this time, CEL-SCI cannot provide the detailed results of this long-term follow-up study of Multikine treatment as the data are currently being prepared for publication. Maximilian de Clara, President of CEL-SCI, states, "These results suggest that Multikine has the potential to bring much needed benefit to patients with head & neck cancer, a disease that has significant morbidity and mortality and for which there has been little improvement in therapy over the last 20 years. We are very excited by these results and hope to repeat these very promising results in our Phase III clinical trial." CEL-SCI received the go-ahead for its proposed Phase III trial from the Canadian drug regulatory authority in August 2005. The same proposed Phase III trial was submitted to and discussed with the United States Food and Drug Administration (FDA) in two separate End of Phase II meetings held during 2005. Following each of these meetings the FDA requested that additional information be provided. CEL-SCI has recently completed the submission of all of the additional information the FDA requested and awaits the FDA's response. Head and neck cancer is an aggressive cancer that affects about 500,000 people per annum worldwide. About 92% of those cases are outside of the U.S., and about two thirds of all cases present with advanced disease. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines and colony-stimulating factors, currently being developed for treatment of cancer. CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine is cleared to enter Phase III clinical trials with advanced primary head and neck cancer patients. Other products, in the pre-clinical stage and funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu. When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward- looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. SOURCE CEL-SCI Corporation   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402  San Diego, CA 92130 Oil, Canada. Lots of chatter about Canadian stocks as traded on the Toronto Stock Exchange. Primarily a resource market, oil, gold and natural gas shares have propelled the TSX index from 9000 in January 2005 to almost 12,000 today. Stocks like oil and gas behemoth Encana (NYSE: ECA) and Barrick Gold (NYSE: ABX) have risen and fallen with the volatile commodity prices and are likely worth a look should one feel that the downtrend is reversing. Canada is the largest single supplier of oil and gas to the US. Lots of focus on the Athabasca Tar sands--which is black, oily gloop that if tapped, could help the US meet its national oil dependence goals without mid-east oil. Some estimates have Alberta sitting on nearly a trillion barrels of oil with varying difficulty of recovery. The Mideast has 685 billion barrels recoverable. The higher oil goes, the more attractive that gloop becomes, as it is extremely expensive to extract. Apparently Calgary and Edmonton have recently been inundated with US Congressional types looking over the goods. Good stuff, eh? Better learn the metric system...   Mac and Geez... McDonalds (NYSE: MCD) is being sued for having not disclosed that it uses wheat and milk in their French fries. Crap, it's likely the only goodness in these heart cloggers. Yes, they should have disclosed these ingredients earlier, but doesn't this just seem like clown-chasing lawyers looking for a cause? The stock's up 20 percent since September and I suspect will continue to appreciate as we get larger and hungrier and this ridiculous case goes away.  Against next year's projected earnings of $2.40 a share, the slimmest thing for MCD is the compelling15 times p/e. What ever happened to boycotts? Guess they weren't profitable enough.   And what's up with that Burger King guy in the mask in their commercials? He creeps me out. Subscribe Information is power and timely information is profitable. Become informed and profit from SmallCapDigest Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the SmallCapDigest Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the SmallCapDigest Member List. Receiving the SmallCapDigest Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the SmallCapDigest recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR Group, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and 150,000 shares of newly issued restricted stock by Cel-Sci for coverage of the Company. Additionally, back in November of 2002, TGR Group LLC was paid a fee of $25,000 and 250,000 shares of newly issued restricted stock of Cel-Sci for coverage of the company until November of 2003. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.